



## Research Agenda

The research committee of the MGFA is committed to supporting research that will ultimately improve the lives of patients with myasthenia gravis and related neuromuscular junction disorders. The committee has identified 4 broad research priorities of unmet need in the field.

- Biomarkers
  - Early diagnosis
  - Predictors of clinical outcome
  - Predictors of response to immunosuppressive therapy
  - Biomarkers for use in clinical trials
- Mechanisms of disease
  - Basic mechanisms of disease
  - How loss of self-tolerance is sustained throughout the disease course
- Therapeutic strategies
  - Development of new therapeutic targets
  - Targeted therapies that hopefully prevent widespread immunosuppression and off-target side effects
  - Optimizing treatment strategies with existing therapies
- Improving patient outcomes
  - The patient perspective on their disease, its impact on their daily life, and treatment considerations that are most important to them
  - Collateral effects of MG and its' treatment such as associated medical conditions, treatment related side effects, and financial considerations.

Though this research agenda is intended to guide researchers towards topics that are important to the MGFA MSAB, the research committee will accept proposals outside of these priority areas and is committed to supporting the best science.